- F32 -

Discovering the Future of Cardiovascular Medicine CVPath Yearly Summary 2024 CVPath Yearly Summary 2024 Aloke Finn MD President and Chief Scientific Officer Dear Friends and Colleagues of CVPath On Risk Factors Favoring Plaque Erosion CVPath scientists recently published a review in the journal Current Atherosclerosis Reports. The review focuses on the risk factors CD163 Macrophages Induce EndothelialtoMesenchymal Transition in Atheroma CD163 macrophages are a type of immune cell that can clean up hemorrhage lesions. Intraplaque hemorrhage IPH is one of Consultation Services The CVPath Institute facility was designed to provide expert translational benchtobedside research services. Our team of experts has decades of experience in medical device evaluation and is able to provide guidance and advice on device safety mechanism of action studies or FDA responses.